english.prescrire.org > Prescrire International > N°53 - June 2001

n°53

June 2001

Issue Contents
Editorial

WHO essential drugs, except for the poor

p.66

Marketing Authorisations


C1 esterase inhibitor: a major advance in emergency treatment of hereditary angioneurotic oedema

p.67-70

Hereditary angioneurotic oedema: a rare but potentially life-threatening condition

p.68-69

Amprenavir, another HIV protease inhibitor: no proven advance

p.70-72

Leuprorelin and triptorelin: preoperative treatment of uterine leiomyoma: no proven value

p.73-75

Uterine leiomyoma: only treat symptomatic women

p.74

Anastrozole: no advantage over tamoxifen in advanced-stage breast cancer

p.76-77

Verteporfin in combination with laser therapy: helpful in some forms of age-related macular degeneration

p.78-81

Age-related macular degeneration

p.80-81

Pravastatin: further assessment in heart transplantation is needed

p.95

Sodium phenylbutyrate: useful in urea synthesis disorders due to enzyme deficiency

p.95

Adverse Effects


Ocular adverse effects of alendronic acid

p.82

Adverse effects of rofecoxib (continued)

p.82-83

Myocarditis due to clozapine

p.83

Reviews


Acupuncture: searching for benefits

p.84-88

Does acupuncture have specific antiemetic effects?

p.85

Intrauterine devices: antibiotic prophylaxis not necessary during insertion

p.89

Medical treatment of chronic heart failure

p.94

Antiinflammatory + antimicrobial eye drops: no clinical value after cataract surgery

p.94

Persona°: a natural contraceptive method with misleading marketing

p.95

Outlook


Essential drugs concept: still valid

p.90-93

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe